Literature DB >> 15542638

A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells.

Jason S Knight1, Nikhil Sharma, Danielle E Kalman, Erle S Robertson.   

Abstract

The Epstein-Barr virus (EBV) nuclear antigen 3C (EBNA3C) is a virus-encoded latent antigen essential for primary B-cell transformation. In this report we demonstrate that although the carboxy terminus of EBNA3C predominantly regulates cyclin A-dependent kinase activity, the region of greatest affinity for cyclin A lies within the EBNA3 amino-terminal homology domain of EBNA3C. Detailed mapping studies employing both in vitro binding assays and coimmunoprecipitation experiments implicated a small region of EBNA3C, amino acids 130 to 159 within the EBNA3 homology domain, as having the greatest affinity for cyclin A. The EBNA3 homology domain has the highest degree of amino acid similarity (approximately 30%) between the EBNA3 proteins, and, indeed, EBNA3B, but not EBNA3A, showed binding activity with cyclin A. We also show that EBNA3C binds to the alpha1 helix of the highly conserved mammalian cyclin box, with cyclin A amino acids 206 to 226 required for strong binding to EBNA3C amino acids 130 to 159. Interestingly, EBNA3C also bound human cyclins D1 and E in vitro, although the affinity was approximately 30% of that seen for cyclin A. Previously it was demonstrated that full-length EBNA3C rescues p27-mediated suppression of cyclin A-dependent kinase activity (J. S. Knight and E. S. Robertson, J. Virol. 78:1981-1991, 2004). It was also demonstrated that the carboxy terminus of EBNA3C recapitulates this phenotype. Surprisingly, the amino terminus of EBNA3C with the highest affinity for cyclin A was unable to rescue p27 suppression of kinase activity and actually downregulates cyclin A activity when introduced into EBV-infected cells. The data presented here suggests that the amino terminus of EBNA3C may play an important role in recruiting cyclin A complexes, while the carboxy terminus of EBNA3C is necessary for the functional modulation of cyclin A complex kinase activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542638      PMCID: PMC524968          DOI: 10.1128/JVI.78.23.12857-12867.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha.

Authors:  M A Cotter; E S Robertson
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

2.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.

Authors:  M A EPSTEIN; B G ACHONG; Y M BARR
Journal:  Lancet       Date:  1964-03-28       Impact factor: 79.321

3.  Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.

Authors:  S A Radkov; M Bain; P J Farrell; M West; M Rowe; M J Allday
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis.

Authors:  C Subramanian; M A Cotter; E S Robertson
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

5.  Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site.

Authors:  B Zhao; C E Sample
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 6.  The Epstein Barr nuclear antigen EBNA3C regulates transcription, cell transformation and cell migration.

Authors:  Chitra Subramanian; Jason S Knight; Erle S Robertson
Journal:  Front Biosci       Date:  2002-03-01

7.  Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis.

Authors:  G A Parker; R Touitou; M J Allday
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

8.  Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription.

Authors:  J C Aster; E S Robertson; R P Hasserjian; J R Turner; E Kieff; J Sklar
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

9.  Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.

Authors:  B A Schulman; D L Lindstrom; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

10.  Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription.

Authors:  S A Radkov; R Touitou; A Brehm; M Rowe; M West; T Kouzarides; M J Allday
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

View more
  32 in total

1.  Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth.

Authors:  Seiji Maruo; Yi Wu; Taku Ito; Teru Kanda; Elliott D Kieff; Kenzo Takada
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

2.  SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen.

Authors:  Jason S Knight; Nikhil Sharma; Erle S Robertson
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

3.  EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes.

Authors:  Elena Kashuba; Mariya Yurchenko; Surya Pavan Yenamandra; Boris Snopok; Maria Isaguliants; Laszlo Szekely; George Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

4.  Deregulation of the cell cycle machinery by Epstein-Barr virus nuclear antigen 3C.

Authors:  Pankaj Kumar; Masanao Murakami; Rajeev Kaul; Abhik Saha; Qiliang Cai; Erle S Robertson
Journal:  Future Virol       Date:  2009-01       Impact factor: 1.831

5.  Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.

Authors:  Gemma L Kelly; Anne E Milner; Rosemary J Tierney; Debbie S G Croom-Carter; Markus Altmann; Wolfgang Hammerschmidt; Andrew I Bell; Alan B Rickinson
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter.

Authors:  Carmilia Jiménez-Ramírez; Andrew J Brooks; Linus Plym Forshell; Konstantin Yakimchuk; Bo Zhao; Tacha Zi Fulgham; Clare E Sample
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1.

Authors:  Sungwook Lee; Shuhei Sakakibara; Seiji Maruo; Bo Zhao; Michael A Calderwood; Amy M Holthaus; Chiou-Yan Lai; Kenzo Takada; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

8.  Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification.

Authors:  Robert E White; Ian J Groves; Ernest Turro; Jade Yee; Elisabeth Kremmer; Martin J Allday
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

9.  Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities.

Authors:  Fuming Yi; Abhik Saha; Masanao Murakami; Pankaj Kumar; Jason S Knight; Qiliang Cai; Tathagata Choudhuri; Erle S Robertson
Journal:  Virology       Date:  2009-04-24       Impact factor: 3.616

10.  EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases.

Authors:  Hem Chandra Jha; Jie Lu; Abhik Saha; Qiliang Cai; Shuvomoy Banerjee; Mahadesh A J Prasad; Erle S Robertson
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.